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The accuracy of the 13C-methacetin breath test (13C-MBT) in diﬀerentiating between various stages of liver disease is not clear.
A cross-sectional study of Asian patients was conducted to examine the predictive value of the 13C-MBT in various stages of
chronic liver diseases. Diagnostic accuracy of the breath test was determined by sensitivity, speciﬁcity, positive predictive value,
negative predictive value, and area under the curve analysis. Seventy-seven patients (47 men/30 women, mean age 50 ± 16 years)
were recruited. Forty-seven patients had liver cirrhosis (Child Pugh A = 11, Child Pugh B = 15, and Child Pugh C = 21), 21 had
ﬁbrosis,and9hadchronicinﬂammation.The sensitivityandpositivepredictive valueforliverﬁbrosis,cirrhosis (allstages),Child-
Pugh A, Child-Pugh B, and Child-Pugh C were 65% and 56%, 89% and 89%, 67% and 42%, 40% and 40%, and 50% and 77%,
respectively. Area under curve values for ﬁbrosis was 0.62 (0.39–0.86), whilst that for cirrhosis (all stages) was 0.95 (0.91–0.99).
The 13C-methacetin breath test has a poor predictive value for liver ﬁbrosis but accurately determines advanced cirrhosis.
1.Background
The prognosis and management of chronic liver diseases
usually requires knowledge of the stage and progression of
disease. Liver biopsy, which is the gold standard in determin-
ing liver ﬁbrosis and cirrhosis, is invasive and is associated
with morbidity and mortality risks [1]. Furthermore, sam-
pling variability can be found in 15%–30% of biopsies [2],
anditisnotused repeatedly tofollow-uppatients. Therefore,
there is an increasing need for alternative noninvasive meth-
ods to diagnose liver ﬁbrosis and cirrhosis.
Several quantitative liver function tests have been pro-
posed to measure the functional hepatic mass [3]. However,
these tests, although accurate, are cumbersome to perform
and impractical in clinical settings. The Child-Pugh [4, 5]
classiﬁcation still remains the most widely used parameter
ofliverfunction. However, thisclassiﬁcation doesnot strictly
reﬂect the quantitative functional liver reserve, and its use-
fulness is limited by concomitant therapy with albumin, for
example,and subjectivityonthedegreeofascitesandhepatic
encephalopathy in an individual patient.
Currently, several 13Cb r e a t ht e s t sb a s e do nt h eu s eo f
labeled substrates selectively metabolized within the liver
are available to noninvasively assess hepatocellular function.
Amongst the various substrates utilized to evaluate quantita-
tive liver function, the 13C methacetin breath test (MBT) has
shown tobe most promising [6–8]. 13CMethacetin, aderiva-
tive of phenacetin, undergoes O-demethylation through the
hepatic mixed oxidase system to acetaminophen and car-
bon dioxide. Compared with other 13C-labeled substrates,
Methacetin is metabolized faster, rapidly cleared from the
blood stream, safe, and cheap [9]. Several studies have
demonstrated that the MBT reliably diﬀerentiates between
healthy controls and patients with established cirrhosis
[6, 10–12]. However, diﬀerentiating between patients with
and without cirrhosis alone has limited value, as this can2 Gastroenterology Research and Practice
be performed reliably with routine clinical methods. A
noninvasive tool to assess progression of liver disease in
noncirrhotic (i.e., from chronic inﬂammation to ﬁbrosis)
andcirrhotic(fromChild-PughgradeAtoC)patientswould
have greater utility in routine clinical practice. At present,
many of the treatment/management algorithms for diseases
such as the chronic viral hepatitis and nonalcoholic fatty
liver disease require the conﬁrmation of ﬁbrosis/cirrhosis for
either initiation or modiﬁcation of therapy [13, 14]. To date,
there is limited information on the MBT and its accuracy
in diﬀerentiating between various grades of chronic liver
disease of diverse aetiologies.
We aimed toassess the accuracyofthe MBTin predicting
liver ﬁbrosis and grades of cirrhosis amongst patients with
chronic liver diseases compared to the established clinical
methods in our population.
2.Methods
2.1. Study Population. Consecutive patients from this multi-
racial Asian population attending the gastroenterology
outpatient and inpatient facilities of 2 institutions were
prospectively recruited. All patients who had chronic liver
disease of various aetiology and grades of liver disease were
excluded. Informed consent from all patients and local
ethical approval (The Ethical Committee, Medical Faculty,
University Kebangsaan Malaysia and Medical Faculty, Uni-
versity Malaya) were obtained prior to the study. Patients
withthefollowing characteristicswereexcluded:thosetaking
drugs with modulating capacity on P450 cytochrome activ-
ity, patients with portal vein thrombosis, heavy smokers
(>10/day for >1 year), those with chronic lung diseases, and
severe comorbid diseases.
2.2. Conﬁrmation of Liver Disease. All patients had an estab-
lished diagnosis of liver disease based on a combination of
clinical, biochemical and radiological features. Noncirrhotic
patients were diagnosed by histology. The liver histology
was classiﬁed by an experienced pathologist according to the
Scheuer classiﬁcation [15]. The classiﬁcation categorizers 5
diﬀerent stages of ﬁbrosis: stage 0—no ﬁbrosis, stage 1—
enlarged ﬁbrotic portal tracts, stage 2—periportal or portal-
portal septa, stage 3—ﬁbrosis with architectural distortions,
and stage 4—cirrhosis. Liver biopsies were performed in
all cases at least 2weeks (ranging from 14–23 days) before
having the MBT. Child-Pugh grade A disease was diagnosed
in patients with histological conﬁrmation of cirrhosis but
no features of hepatic decompensation. Advanced cirrhosis
(Child-Pugh grade B and C) was diagnosed in individuals
with deﬁnite portal hypertension, clinical features of decom-
pensation and/or radiological imaging.
2.3. 13CM e t h a c e t i nB r e a t hT e s t .13C-MBT was performed
after at least 8 hours of fasting. A baseline breath sample
was taken to evaluate the amount of 13C present at baseline
(international standard ratio = 0.1%). The patients were
then given 75mg of 13C Methacetin (99% 13C, Cambridge
Isotope Laboratories, Andover, Mass, USA) dissolved in
50ml of tea to drink. Breath samples were obtained by slow
expiration through a tube into a breath sample bag, after
a deep inspiration. Breath samples were collected at ten-
minute intervals for the ﬁrst hour and at twenty-minute
intervals for up to 120minutes after substrate admin-
istration. All subjects were required to be at rest and
without drinking and eating for the duration of the test.
The 13CO2/12CO2 isotope ratio in the breath samples
was analyzed by nondispersive isotope-selective infrared
spectrometry (Wagner Analysentechnik, Bremen,Germany)
[16]. The δ values obtained were related to the baseline
δ values. The percentage of 13C exhaled was calculated
assuming a CO2 production rate of 5mmol/minm2.T h e
results were expressed as the cumulative percentage (%) of
the administered dose of 13C recovered over time, which
corresponded to the administered dose of 13Cp e rh o u r .
2.4. Study Analysis and Statistics. Discriminatory ability of
the 13C MBT was quantiﬁed by using an area under
the receiver operating curve [17]. The MBT value that
correctly classiﬁed all subjects had an area of 1.0 (perfect
discrimination), and the value with no discriminatory
power had an area of 0.5 or less. AUC values of 0.7-0.8
and >0.8 were considered to represent reasonable and good
discrimination [18] respectively. The sensitivity, speciﬁcity,
positive predictive value (PPV) and negative predictive value
(NPV) were additionally determined to assess the accuracy
of predetermined 13CM B T“ c u t o ﬀ ”v a l u e s .
13C breath test data were expressed as means with
standard deviation, and comparisons between patients with
various liver diseases were performed using the Mann-
Whitney U test (i.e., nonparametric data). Statistical signiﬁ-
cance was assumed at a P value of <. 05.
3.Results
Seventy-seven people (47 men/30 women, mean age 50 ±
16 years) were recruited for the study between March 2006
to March 2007. The majority of patients had chronic (viral)
hepatitis B (32.5%) and C (26.0%) infection. Forty-seven
patients had liver cirrhosis and twenty one patients had
ﬁbrosis at various stages..Further 9 patients had chronic
inﬂammation ofvarious aetiology (Table 1). Among patients
with cirrhosis, the severity of liver disease were as follows:
Child Pugh A n = 11, Child Pugh B n = 15, and Child Pugh
C n = 21. Stages of ﬁbrosis in noncirrhotic patients were as
follows: stage 1 n = 10,stage 2 n = 7, stage 3 n = 3, and stage
4 n = 1( Table 1).
Meancumulativerecoverypercentages(metaboliccapac-
ity) at both 40 and 120minutes were compared between
patients with various stages of liver disease (Table 2). At
40minutes of metabolic capacity, MBT values were sig-
niﬁcantly lower in patients with cirrhosis compared to those
without (0.25 ± 0.22 versus 0.77 ± 0.19, P<. 0001). MBT
values were signiﬁcantly diﬀerent between all grades of liver
cirrhosis (Table 2). However, in noncirrhotic patients (n =
30), no signiﬁcant diﬀerences in MBT values were noted
between cases with and without ﬁbrosis (0.72 ± 0.17 versusGastroenterology Research and Practice 3
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Figure 1: Receiver operating characteristic curve analysis of cumu-
lativepercent oxidationofmethacetin at40minutesinpatientswith
and without cirrhosis.
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Figure 2: Receiver operating characteristic curve analysis of cumu-
lativepercent oxidationofmethacetin at40minutesinpatientswith
and without ﬁbrosis (i.e., noncirrhotic).
0.80 ± 0.25, P = .33). Similar results were obtained for
cumulative recovery percentages at 120 minutes (Table 2).
Discriminatory ability of the MBT was assessed based
on the 40minute cumulative recovery percentages (Table 3).
The MBT was able to discriminate well between patients
with and without cirrhosis (AUC 0.91, 95% CI = 0.82–
0.99)and between Child-PughC cirrhosis and those without
Table 1:Baselinecharacteristicsofthestudiedpopulation(n = 77).
Gender (male/female) 47 (61%)/30 (39%)
Age (years) 50 ± 16
Ethnic groups
Malay/Chinese/Indian 27 (35%)/37 (48%)/13 (17%)
Aetiology#
HBV 25 (32.5%)
HCV 20 (26.0%)
NAFLD 9 (11.7%)
Cryptogenic 7 (9.1%)
Myeloﬁbrosis 1 (1.3%)
Alcohol 12 (15.6%)
PBC/AIH 3 (3.8%)
Cirrhosis/non-cirrhosis
Child-Pugh class A 11 (23.4%)
Child-Pugh class B 15 (31.9%)
Child-Pugh class C 21 (44.7%)
Stages of ﬁbrosis
Stage 0 9 (30.0%)
Stage 1 10 (33.3%)
Stage 2 7 (23.3%)
Stage 3 3 (10.0%)
Stage 4 1 (3.33%)
#Abbreviations: HBV: chronic hepatitis B; HCV: chronic hepatitis C;
NAFLD: non alcoholic fatty liver disease; PBC: primary biliary cirrhosis;
AIH: autoimmunehepatitis.
(AUC 0.91, 95% CI = 0.82–0.99), as illustrated in Figure 1.
However, it had poor discriminatory power for Child-Pugh
A (AUC 0.47) and less than reasonable diﬀerentiation for
Child-Pugh B (AUC 0.69) and liver ﬁbrosis (AUC 0.67). The
l a t t e ri ss h o w na sa ne x a m p l ei nFigure 2.
The accuracy of predetermined “cut-oﬀ ”M B Tv a l u e s
for various stages of liver disease are highlighted in Table 3.
Brieﬂy, predicted “cut-oﬀ ” values of the MBT for liver
ﬁbrosis had a 65% sensitivity and a PPV of 56%, whilst
sensitivity and PPV for cirrhosis (all stages) were 89% and
89% respectively. Sensitivity and PPV for Child-Pugh A, B,
and, C were 67%, 40%, and 50% and 42%, 40%, and 77%,
respectively (Table 3). Conversely, speciﬁcity and NPV of the
MBT were reasonable: ﬁbrosis 82% and 87%, cirrhosis (all
stages) 83% and 83%, Child-Pugh A cirrhosis 83% and 93%,
Child-Pugh B cirrhosis 85% and 85%, and Child-Pugh C
cirrhosis 95% and 84% (Table 3).
None of the patients in the study sustained an adverse
reaction to methacetin.
4.Discussion
The MBT has been purported as a suitable alternative to
standard clinical methods in assessing liver function such
as the Child-Pugh score/grade [19, 20]. However, clinicians
managing patients with chronic liver disease require a
diagnostic measurement/modality that reliably characterises
the natural history of chronic liver disease, that is, from4 Gastroenterology Research and Practice
Table 2: Mean values of the cumulative percent oxidation of the 13C-MBT at 40 and 120 mins in various stages of chronic liver disease.
Stages of liver disease n Cum.
40minsa
Mean
diﬀerence
(95% CI)
P Cum.
120minsb
Mean
diﬀerence
(95% CI)
P
Fibrosis 21 0.72 ± 0.17 −0.07 .33 0.85 ± 0.14 −0.09 .11
Nonﬁbrosis/
inﬂammation
9 0.80 ± 0.25 (−0.24 to
0.08) 0.94 ± 0.19 (−0.22 to
0.03)
Cirrhosis 47 0.25 ± 0.22 −0.51 <.0001 0.43 ± 0.26 −0.47 <.0001
Noncirrhosis 30 0.77 ± 0.19 (−0.61 to
−0.41) 0.89 ± 0.15 (−0.57 to
−0.36)
CPA∗ cirrhosis 12 0.45 ± 0.18 −0.31 <.0001 0.64 ± 0.19 −0.25 <.0001
noncirrhosis 29 0.76 ± 1.89 (−0.44 to
−0.18) 0.89 ± 0.15 (−0.36 to
−0.13)
CPB# cirrhosis 15 0.26 ± 0.17 −0.41 <.0001 0.46 ± 0.23 −0.36 <.0001
CPA/noncirrhosis 41 0.67 ± 0.23 (−0.54 to
−0.28) 0.82 ± 0.20 (−0.49 to
−0.24)
CPC∗∗cirrhosis 21 0.12 ±0.19 −0.44 <.0001 0.28 ± 0.22 −0.45 <.0001
Non-CPC cirrhosis 56 0.56 ± 0.28 (−0.57 to
−0.30) 0.72 ± 0.26 (−0.57 to
−0.31)
∗Child-Pugh A, #Child-Pugh B, and ∗∗Child-Pugh C.
aNormal range: 0.90–1.20.
bNormal range: 0.80–1.10.
Table 3: Predictive value of the 13C-MBT in various stages of liver disease based on the cumulative recovery of oxidation at 40 minutes.
Sensitivity (95% CI) Speciﬁcity (95% CI) PPV (95% CI) NPV (95% CI) AUC (95% CI)
Fibrosis 65 (44–86) 82 (72–92) 56 (36–76) 87 (78–96) 0.62 (0.39–0.86)
Cirrhosis(all stages) 89 (80–98) 83 (69–97) 89 (80–98) 83 (69–97) 0.95 (0.91–0.99)
nonﬁbrotic inﬂammation to ﬁbrosis and eventually to the
various stages of cirrhosis. In previous studies, the 13C-
MBThasbeendemonstratedtoreliablydiﬀerentiatebetween
healthy adult controls and patients with liver cirrhosis [19,
20]. A few recent publications have also demonstrated that
liver ﬁbrosis can be predicted in patients with chronic viral
hepatitis [21, 22]. Dinesen et al. compared the diagnostic
accuracy of using 13C-MBT with several noninvasive tests
like the APRI, AAR, and Fibroindex and found that the 13C-
MBT was more reliable in predicting advanced ﬁbrosis and
cirrhosis in patients with chronic hepatitis C [22]. Lalazar et
al. also demonstrated that by using a continuous automatic
molecular correlation spectroscopy BreathID, an accurate
detection of liver inﬂammation and ﬁbrosis was obtained
on patients with chronic hepatitis C with normal ALT levels
[23]. However, diﬀerentiationbetweenstages ofchronic liver
disease and cirrhosis has not been established.
In this pragmatic study of Asian patients with chronic
liver disease of various aetiologies, we have demonstrated
that the MBT was only of value in discriminating between
cases with and without cirrhosis, particularly in those with
more advanced cirrhosis (Child-Pugh B and C). The MBT
could not reliably diﬀerentiate between patients with and
without ﬁbrosis in noncirrhotic patients. This observation,
as assessed by the AUC, was further supported by diﬀerences
in the mean cumulative oxidation capacity values. Addition-
ally, predicted values of the MBT for various stages of liver
d i s e a s ew e r es h o w nt oh a v eal o ws e n s i t i v i t ya n dP P Vf o r
hepaticﬁbrosis and some stagesofcirrhosis, butareasonable
speciﬁcity and NPV.
Sensitivity, speciﬁcity, PPV, and NPV of the MBT for
predicting cirrhosis were similar to a recent study of 96
German patients with chronic hepatitis C (sensitivity 92.6%,
speciﬁcity 84.1%, PPV 69.4%, and NPV 96.7%) but very
diﬀerent in the case of hepatic ﬁbrosis [22]. Similarly, our
results are consistent with a previous Spanish study of 48
patients with various stages of chronic liver disease, which
demonstratedthattheMBTwassensitive atdetectingcirrho-
sis but poor at diﬀerentiating between chronic hepatitis and
early stages of cirrhosis [8]. However, these results have been
challenged by a few recent studies that have demonstrated
reasonable diﬀerentiation between stages of cirrhosis in
patientswithmostly hepatitisC-related liverdisease [19, 24].
The most useful expression of MBT kinetic parameters
from a diagnostic perspective is the cumulative percent
oxidation at a particular time period. In the literature, there
has been some variation to the precise cumulative recovery
time selected to determine hepatic function. Cumulative
recovery times of 10 minutes [8], 15 minutes [21], 30
minutes [12, 19], and 60 and 120 minutes [20] have been
reported in various populations to be the ideal predictive
time of hepatic function. Variations in gastric emptying time
are believed to account for some of these diﬀerences. How-
ever, it is now suggested that cumulative recovery periodsGastroenterology Research and Practice 5
beyond 60 minutes are not necessary, as the results for
cumulative recovery are best seen in periods <60 minutes
[21].Inviewofthesedata,theoxidationperiodof40minutes
that was used in this study, based on the IRIS manufac-
turer’s recommendation, seems reasonable and appropriate.
Furthermore, the hepatic oxidation of MBT takes account of
body surface area and has been shown to be reproducible in
non-Western ethnic groups as well [25].
A possible explanation for the poor diagnostic value
of the MBT in our patient sample may have been due
to the aetiology of liver disease in this region. Most of
the studies that have examined the diagnostic ability of
the MBT have been performed in Western patients with
chronic hepatitis C. In the Asia-Paciﬁc region, hepatitis B
remains the commonest cause of chronic liver disease [13],
and this was reﬂected in our patient sample. Whilst hepatic
function in cirrhosis is fairly similar regardless of aetiology,
it is possible that variations in noncirrhotic liver disease
hepatocyte function due to diﬀerent aetiologies may account
for the MBT results observed.
5.Conclusions
We conclude that the 13C-MBT is useful in the diagnosis
of advanced cirrhosis in Asian patients with chronic liver
disease. However, this study has demonstrated that the MBT
does not reliably diﬀerentiate between noncirrhotic and
various stages of cirrhosis in our group of patients, which
limits its application in routine clinical practice at this stage.
Further studies are required to determine if modiﬁcations
of the MBT or substrate are required to improve diagnostic
ability in Asian patients with chronic liver disease.
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